FDA Committee Votes Against Approval of Lykos Therapeutics’ MDMA Treatment for PTSD

In a majority vote, the Psychopharmacologic Drugs Advisory Committee cited concerns regarding the data presented for MDMA as a treatment for post-traumatic stress disorder.

Leave a Reply

Your email address will not be published. Required fields are marked *